DrugPatentWatch Database Preview
Drugs in Development Information for SUVN-502
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for SUVN-502?
SUVN-502 is an investigational drug.
There have been 7 clinical trials for SUVN-502.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Cognition Disorders, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Suven Life Sciences Limited and [disabled in preview].
There are four US patents protecting this investigational drug and ninety-eight international patents.
Summary for SUVN-502
| US Patents | 4 |
| International Patents | 98 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2015-09-01) |
| Vendors | 5 |
Recent Clinical Trials for SUVN-502
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Safety, and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without Cataplexy | Suven Life Sciences Limited | Phase 2 |
| Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects | Suven Life Sciences Limited | Phase 1 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects | Suven Life Sciences Limited | Phase 1 |
Clinical Trial Summary for SUVN-502
Top disease conditions for SUVN-502
Top clinical trial sponsors for SUVN-502
US Patents for SUVN-502
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SUVN-502 | Start Trial | Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite | SUVEN SCIENCES LIMITED (Hyderabad, Andhra, IN) | Start Trial |
| SUVN-502 | Start Trial | Tetracyclic 3-substituted indoles having serotonin receptor affinity | Suven Life Sciences Limited (Hyderabad, Adhra Pradesh, IN) | Start Trial |
| SUVN-502 | Start Trial | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | Suven Life Sciences Limited (IN) | Start Trial |
| SUVN-502 | Start Trial | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-- 1H-indole dimesylate monohydrate | SUVEN LIFE SCIENCES LIMITED (Hyderbad, IN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SUVN-502
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SUVN-502 | Australia | 2014404000 | 1989-12-31 | Start Trial |
| SUVN-502 | Brazil | 112017002921 | 1989-12-31 | Start Trial |
| SUVN-502 | Canada | 2957497 | 1989-12-31 | Start Trial |
| SUVN-502 | China | 106794170 | 1989-12-31 | Start Trial |
| SUVN-502 | Denmark | 3180001 | 1989-12-31 | Start Trial |
| SUVN-502 | Eurasian Patent Organization | 031319 | 1989-12-31 | Start Trial |
| SUVN-502 | Eurasian Patent Organization | 201790396 | 1989-12-31 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
